• Product NameNFkB-p105(Phospho-Ser927) Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
• ApplicationsWB IHC IF
• Species ReactivityHu Ms Rt
• SpecificityThe antibody detects endogenous level of NFkB-p105 only when phosphorylated at serine 927.
• Immunogen TypePeptide-KLH
• Immunogen DescriptionPeptide sequence around phosphorylation site of serine 927 (C-D-S(p)-G-V) derived from Human NFkB-p105.
• Target NameNFkB-p105
• ModificationPhospho
• Alternative Names    DNA-binding factor KBF1; EBP-1; NF-kappa-B1 p84/NF-kappa-B1 p98; NFKB1; NFkB-p50
• Accession No. Swiss-Prot: P19838
  NCBI Protein: NP_001158884.1
• UniprotP19838
• Gene ID4790;
• Concentration 1.0mg/ml
• Formulation Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Storage Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

• Predicted MW: 120 kd
  Western blotting: 1:500~1:1000
  Immunohistochemistry: 1:50~1:100
  Immunofluorescence: 1:100~1:200

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively.

Hou S, et al. (2003) J Biol Chem. 278(46): 45994-45998.
Baeuerle P A, et al. (1994) Annu Rev Immunol. 12:141-179.
Baeuerle P A, et al. (1996) Cell 87:13-20.
Haskill S, et al. (1991) Cell 65:1281-1289.
 

• Western blot analysis of extracts from HL60 cells untreated or treated with TNF-a using NFkB-p105(Phospho-Ser927) Antibody #11312.
• Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NFkB-p105(Phospho-Ser927) Antibody #11312(left) or the same antibody preincubated with blocking peptide(right).
• Immunofluorescence staining of methanol-fixed Hela cells using NFkB-p105(Phospho-Ser927) Antibody #11312.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting